We are one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (“APIs”), with a focus on research and development. As of March 31, 2021, we have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic. We have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-55% and 65-70%, respectively, of the API exports from India, between Fiscal 2017 and 2020. We were among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume (Source: CRISIL Report).
IPO Timeline:
| Date of filing | 17 May 2021 |
| IPO Open | Yet to be declared |
| IPO close | Yet to be declared |
| Allotment Date | Yet to be declared |
| Initiation of Refunds | Yet to be declared |
| Credit of shares in Demat | Yet to be declared |
| Listing on exchange | Yet to be declared |
Issue Details:
| Exchange | BSE, NSE |
| Issue Type | |
| Face Value | |
| Price Band | |
| Lot Size | |
| Issue Size | |
| Offer for Sale | |
| Fresh Issue |
Subscription Quota:
| Category | Quota |
| QIB | |
| NII | |
| RII | |
| Total |
Subscription Status:
| Category | Subscription |
| QIB | |
| NII | |
| RII | |
| Total |
Profit & Loss Statement (₹ in Cr) :
| 31 Dec 2020 (nine month) | 31 March 2020 | 31 March 2019 | 31 March 2018 | |
| Total Revenue | 268 | 323 | 286 | 222 |
| Total Expense | 153 | 213 | 213 | 191 |
| Profit after Tax | 76.0 | 73.2 | 39.3 | 8.72 |
Other Financials (₹ in Cr) :
| 31 Dec 2020 | 31 March 2020 | 31 March 2019 | 31 March 2018 | |
| Total Equity | 225 | 149 | 94 | 55 |
| Total Liability | 131 | 187 | 159 | 191 |
| Debt to equity | 0.58 | 1.25 | 1.69 | 3.47 |